0A8E Stock Chart & Stats
$8.46
-$0.28(-3.33%)
At close: 4:00 PM EDT
$8.46
-$0.28(-3.33%)
Day’s Range― - ―
52-Week Range$5.26 - $11.27
Previous CloseN/A
Volume1.46K
Average Volume (3M)2.31K
Market Cap
$1.82B
Enterprise Value$1.54K
Total Cash (Recent Filing)$121.75M
Total Debt (Recent Filing)$289.44M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Nov 05, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding182,320,310
10 Day Avg. Volume4,453
30 Day Avg. Volume2,309
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.67Price Target Upside49.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$387.25M
Bulls Say, Bears Say
Bulls Say
Strong Commercial GrowthBroad-based product momentum, led by Recorlev’s 81% growth, is translating into a materially higher revenue outlook. Sustained prescription adoption and commercial execution can expand Xeris’s operating scale and reinforce its position in specialty endocrinology markets over coming quarters.
Improving Margins And Cash GenerationHigh gross margins and positive free cash flow indicate that Xeris’s approved-product portfolio is increasingly supporting internal funding. Continued cash conversion could help finance commercialization and pipeline development while reducing reliance on external capital as the business grows.
Durable Product Protection And PipelineLong-dated Keveyis patent protection supports the durability of an established ultra-rare-disease franchise and may protect future commercial investment. Combined with XP-8121’s patent progress and planned Phase III development, this provides a foundation for extending Xeris’s product portfolio.
Bears Say
Fragile Balance SheetNegative equity and substantial debt leave Xeris with a limited capital cushion relative to its obligations. Although the company retired its 2028 convertible notes, the remaining leverage can constrain financial flexibility and make funding growth or absorbing setbacks more difficult.
GAAP Profitability Remains InconsistentThe company has improved operating performance but has not yet demonstrated consistent bottom-line profitability. Persistent or recurring losses can limit retained capital, reduce resilience during execution challenges, and make future growth depend more heavily on successful commercial scaling.
Higher Spending Raises Execution RiskExpanded commercial and research investment may support Recorlev growth and XP-8121 development, but it also increases the cost base before those initiatives fully mature. If revenue expansion slows, higher expenses could pressure cash generation and delay sustainable GAAP profitability.
Xeris Pharmaceuticals News
0A8E FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest share price was $5.26 and its highest was $11.27 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.82B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 34 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.192.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,320,310 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -12.329%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0A8E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (49.72% Upside)
$12.67 (49.72% Upside)
Blogger Sentiment
Bullish
GB:0A8E Sentiment 85%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
0A8E Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.View all GB:0A8E earnings summaries0A8E Stock 12 Month Forecast
Average Price Target
$12.67
▲(49.72% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―